IntelGenx (TSXV:IGX; OTCQX:IGXT) announced it received a patent allowance from the United States Patent and Trademark Office (USPTO).
As quoted in the press release:

This film formulation patent covers Montelukast oral film formulations designed for the treatment of neuroinflammation and is intended to protect IntelGenx’ Montelukast VersaFilm™ product.
IntelGenx’ new, soon to be patented Montelukast oral film technology is designed to provide increased plasma concentration as compared with an immediate release oral tablet having an identical loading of Montelukast.
“The granting of this notice of allowance for a formulation specific orange book eligible patent for our Montelukast oral film validates the innovative work carried out on this project by our talented R&D team” said Horst G. Zerbe, CEO of IntelGenx. “While expanding our overall intellectual property portfolio, this new patent also solidifies the potential long-term market exclusivity of our unique Montelukast film product.”

Click here to read the full press release.

Source: www.marketwired.com